-
Mashup Score: 0
Garching / Munich, March 9, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the design for its second phase III trial, COMPOSE (NCT04919226) at the 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference being held in a hybrid format in Barcelona on March 10-11, 2022. The study is designed to evaluate…
Source: itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0
Garching / Munich, January 19, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI), held from January 20 – 22, 2022. COMPOSE will evaluate the company’s lead radiopharmaceutical candidate, ITM-11…
Source: itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
We will be presenting the design of COMPOSE, our 2nd phase III clinical trial with our lead candidate ITM-11 (n.c.a. lutetium-177-edotreotide) in #GEP-NETs at the @ASCO Gastrointestinal Cancers Symposium from Jan 20-22. For more details visit: https://t.co/iM7SVNqiMe https://t.co/mHIJygFHt9
-
-
Mashup Score: 0ISHLT: The International Society for Heart & Lung Transplantation - ISHLT Innovation Challenge Award - 2 year(s) ago
This grant will fund research that tests the utility of the combination of donor-derived cell-free DNA (dd- cfDNA) and gene expression profiling (GEP) in heart transplantation, or utility of dd-cfDNA in lung transplantation. The research will focus on how these noninvasive tools improve outcomes for transplant recipients. Although rates of acute rejection have declined after solid organ…
Source: ishlt.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The NEW #ISHLT Innovation Challenge Award is accepting applications through 31 January. Finalists present their work at #ISHLT2022! Sponsored by @CareDx, the award supports research in #ddcfDNA and #GEP. Learn more and apply at https://t.co/S9eqBOzKml #ISHLTEarlyCareer https://t.co/Aa4m6uz7tH
-
-
Mashup Score: 0
This study demonstrates that CP-GEP can identify patients with a low risk for nodal metastasis. Patients with pT1-2 melanomas have the highest clinical benefit from using the test, where 35% of the patients could forgo a SLNB procedure.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice work from @OlofssonBagge and team: Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma … https://t.co/MrF7aw5aEE #melanoma #GEP
-
-
Mashup Score: 0ISHLT: The International Society for Heart & Lung Transplantation - ISHLT Innovation Challenge Award - 2 year(s) ago
This grant will fund research that tests the utility of the combination of donor-derived cell-free DNA (dd- cfDNA) and gene expression profiling (GEP) in heart transplantation, or utility of dd-cfDNA in lung transplantation. The research will focus on how these noninvasive tools improve outcomes for transplant recipients. Although rates of acute rejection have declined after solid organ…
Source: ishlt.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The new #ISHLT Innovation Challenge Award is accepting applications through 31 January. The award, sponsored by @CareDx, supports research in #ddcfDNA and #GEP, and #ISHLTEarlyCareer professionals are welcome to apply. Learn more and apply at https://t.co/S9eqBOzKml https://t.co/e2AXpWSFps
-
Design of our second ph 3 clinical trial, COMPOSE, with our lead radiopharmaceutical candidate, ITM-11, for the treatment of high grade #GEP-NETs to be presented at this year’s #ENETs conference from March 10-11. For further details visit: https://t.co/HnnMsbxqqb #ENETS22 https://t.co/6JoWKFeoL5